Observing the biotech sector’s stock prices post losses yesterday, Wednesday, Dec. 21 convinced us that investors and traders in the biotech sector might have wrongly interpreted a bipartisan Senate report regarding the high price of drugs.
The report is the outcome of a study that forms the basis of a recommendation that would enable the Congress take the right action against unjustified increases in the prices of decades-old prescription medicines that are still used for certain diseases and have no competition.
Decade old drugs is what investors missed to hear. They surely . . .